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OBJECTIVES We sought to use quantitative markers of the regional left ventricular (LV) response to stress
to infer whether diabetic cardiomyopathy is associated with ischemia.
BACKGROUND Diabetic cardiomyopathy has been identified in clinical and experimental studies, but its cause
remains unclear.
METHODS We studied 41 diabetic patients with normal resting LV function and a normal dobutamine
echo and 41 control subjects with a low probability of coronary disease. Peak myocardial
systolic velocity (Sm) and early diastolic velocity (Em) in each segment were averaged, and
mean Sm and Em were compared between diabetic patients and controls and among different
stages of dobutamine stress.
RESULTS Both Sm and Em progressively increased from rest to peak dobutamine stress. In the diabetic
group, Sm was significantly lower than in control subjects at baseline (4.2  0.9 cm/s vs. 4.7
 0.9 cm/s, p 0.012). However, Sm at a low dose (6.0 1.3), before peak (8.4 1.8), and
at peak stress (8.9  1.8) in diabetic patients was not significantly different from that of
controls (6.3  1.4, 8.9  1.6, and 9.6  2.1 cm/s, respectively). The Em (cm/s) in the
diabetic group (rest: 4.2  1.2; low dose: 5.0  1.4; pre-peak: 5.3  1.1; peak: 5.9  1.5)
was significantly lower than that of controls (rest: 5.8  1.5; low dose: 6.6  1.5; pre-peak:
6.9 1.3; peak: 7.3 1.7; all p 0.001). However, the absolute and relative increases in Sm
or Em from rest to peak stress were similar in diabetic and control groups.
CONCLUSIONS Subtle LV dysfunction is present in diabetic patients without overt cardiac disease. The
normal response to stress suggests that ischemia due to small-vessel disease may not be
important in early diabetic heart muscle disease. (J Am Coll Cardiol 2003;42:446–53)
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A number of experimental, pathologic, and epidemiologic
studies support the existence of diabetic cardiomyopathy
(1), the clinical diagnosis of which is made when systolic
and diastolic left ventricular (LV) dysfunction are present in
diabetic patients without other known cardiac disease (2–4).
As with other conditions where new cardiac imaging tech-
nologies have identified subclinical heart disease (5–7), myo-
cardial backscatter and strain characteristics in patients with
diabetes mellitus have been shown to be abnormal (8,9).
See page 454
Diabetic cardiomyopathy may be an important contribu-
tor to the susceptibility of diabetic subjects to the develop-
ment of heart failure and to their worse outcome with this
condition (10). As treatment to reverse this disorder is more
likely to be effective at an early (preclinical) stage, defining
the mechanism of diabetic cardiomyopathy may be impor-
tant to its selective treatment. However, the etiologic agent
for diabetic heart disease remains undefined—the most
likely contributors being disturbances of cardiac muscle,
pathology involving the cardiac stroma (e.g., fibrosis), or
disease of the small vessels. The separation of these etiolo-
gies is difficult with standard technologies, and given the
asymptomatic status of patients with preclinical disease, a
biopsy study would be difficult to justify.
Small-vessel disease is common in diabetic subjects, such
that this pathology may merely correlate with diabetic heart
disease, perhaps through common mechanisms. If vascular
disease were causative, it might be expected that the
ventricular response to stress would be abnormal. Tissue
Doppler-derived myocardial peak systolic velocity (Sm) and
peak early diastolic velocity (Em) are more sensitive indexes
of LV systolic and diastolic function than conventional
echocardiography and have enabled quantification of sys-
tolic and diastolic function at rest and during stress (11,12).
We therefore sought to apply tissue Doppler indexes of
systolic and diastolic function (Sm and Em) to identify
whether patients with diabetic cardiomyopathy had an
abnormal stress response, implying an etiologic contribution
from small-vessel disease.
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METHODS
Subjects. We studied 41 patients with diabetes mellitus (29
male and 12 female; mean age 59  9 years) and 41 control
patients with a low probability of coronary disease (23 male
and 18 female; mean age 56  8 years). Subjects were
eligible for recruitment if they had an ejection fraction
50% (as assessed by the modified biplane Simpson’s
method), no history of coronary artery disease (CAD), a
normal stress echocardiogram and/or coronary angiogram,
and no LV hypertrophy. Subjects were excluded if they had
abnormal systolic function, moderate to severe valvular
disease, rest or stress wall motion abnormalities, CAD, LV
hypertrophy, atrial fibrillation or other severe arrhythmias,
or congenital heart disease. The control subjects were
considered to have a low probability of coronary disease on
clinical grounds and had a normal dobutamine stress echo-
cardiogram (DbE).
Standard echocardiography. Resting echocardiography
was performed in the left lateral decubitus position, using a
standard commercial ultrasound machine (Vivid 5, GE
Vingmed, Horten, Norway) with a 2.5-MHz phased-array
probe. Images were obtained in the standard tomographic
views of the LV (parasternal long and short axis and apical
four-chamber, two-chamber, and long-axis views). Mitral
inflow velocities were recorded by using conventional
pulsed-wave Doppler echocardiography, positioning a sam-
ple volume at the level of the mitral leaflet tips in the apical
four-chamber view. The peak early diastolic velocity (E),
peak late diastolic velocity (A), E/A ratio, isovolumic
relaxation time, and E-wave deceleration time were mea-
sured on line. All images were saved digitally in raw-data
format to a magneto optical disk (EDM-2300B, Sony
Electronic Inc., Saitama, Japan) for offline analysis.
Left ventricular diameters and wall thicknesses were
measured from the two-dimensional targeted M-mode
echocardiographic tracings in the parasternal long axis,
according to the criteria of the American Society of Echo-
cardiography (13). Fractional shortening was calculated by
the formula: (end-diastolic LV dimension  end-systolic
LV dimension)/end-diastolic LV dimension (14). The LV
mass was determined by Devereux’s formula: LV mass (g)
1.04 ([end-diastolic LV dimension  end-diastolic septal
thickness  end-diastolic posterior wall thickness]3 
[end-diastolic LV dimension]3)  13.6 (15). Left ventric-
ular hypertrophy was defined as LV mass index 131 g/m2
in men and 100 g/m2 in women (16). The LV end-
diastolic and end-systolic volumes at rest were computed
from two- and four-chamber views, using a modified
Simpson’s biplane method, and the LV ejection fraction was
calculated. Each representative value was obtained from the
average of three measurements.
Tissue Doppler imaging and dobutamine stress test.
Myocardial velocities were recorded by activating the color
tissue Doppler function to record low-velocity, high-
intensity myocardial signals at a high frame rate (120
MHz), giving a temporal resolution of 8 ms. Data were
acquired in the apical views to assess myocardial long-axis
function. The imaging angle was adjusted to ensure a
parallel alignment of the beam with the myocardial segment
of interest. After recording resting baseline tissue Doppler
imaging (TDI), dobutamine was administered using a
standard 3-min incremental DbE protocol (5 to 40 g/kg
per min) (17), and TDI was recorded before each incre-
ment. Patients who failed to achieve 85% of their maximal
age-predicted heart rate (HR) were given 1 mg atropine in
increments of 0.25 mg until the target HR was achieved.
The 12-lead electrocardiogram (Marquette Case 15, Mar-
quette, Wisconsin) was monitored throughout, and blood
pressure (BP) was recorded at rest and at 3-min intervals
during infusion and recovery. End points of the stress
protocol were completion of the protocol, progressive or
severe chest pain, serious ventricular arrhythmia, systolic BP
240 mm Hg, symptomatic hypotension or systolic BP
100 mm Hg, or intolerable side effects. Data were saved in
digital format for offline analysis.
Regional wall motion analysis was assessed using a
standard 16-segment model (18) of the four tomographic
views of the LV by two observers blinded to the patient’s
clinical and angiographic data. Wall motion was scored as
normal, mildly hypokinetic, severely hypokinetic, and aki-
netic; patients with hypokinesia or akinesia at any stage of a
dobutamine stress test were not recruited into the study.
Each of six walls from the three apical views was divided
into basal, mid, and apical segments. Using offline analysis
software, segmental velocity profiles within a 9  9 pixel
sample volume were derived at baseline, low dose, pre-peak,
and peak stress at the basal aspect of the basal, mid, and
apical segments of the septal, lateral, anteroseptal, posterior,
inferior, and anterior LV walls from base to apex (Echopac,
GE Vingmed, Horten, Norway). Myocardial peak systolic
and early diastolic filling velocities in each segment were
measured and averaged for each patient at rest and each
stage of dobutamine stress (Fig. 1). Thirty-one segments
were excluded from the analysis, including segments that
were poorly visualized or with a 20° angle between their
long axis and the Doppler beam, or with a change of image
orientation during stress.
Abbreviations and Acronyms
A  mitral peak late diastolic velocity
BP  blood pressure
CAD coronary artery disease
DbE  dobutamine stress
echocardiogram/echocardiography
E  mitral peak early diastolic velocity
Em  myocardial peak early diastolic velocity
HR  heart rate
LV  left ventricle/ventricular
Sm  myocardial peak systolic velocity
TDI  tissue Doppler imaging
447JACC Vol. 42, No. 3, 2003 Fang et al.
August 6, 2003:446–53 Reduced Myocardial Velocities in the Diabetic Heart
Figure 1. Measurement of myocardial peak systolic velocity (Sm) and myocardial peak early diastolic velocity (Em) at rest (left; heart rate 69 beats/min) and at peak (right; heart rate 128 beats/min) in a















Coronary angiography. Coronary artery disease was ex-
cluded during routine coronary angiography, using the
Judkin’s technique, in 13 patients. Coronary stenoses were
quantitated using edge-detection software (Philips, Best,
Netherlands); a diameter reduction 50% was considered
significant. The interval between DbE and coronary angiog-
raphy was 4  2 weeks.
Inter-observer and intra-observer variability. Inter-
observer and intra-observer variability in the measurement
of Sm and Em were evaluated in 16 subjects (8 each from
the diabetic and control groups) randomly selected from the
82 subjects. Intra-observer reproducibility of Sm and Em
was assessed by one observer at separate times (at least two
weeks). To test inter-observer variability, another observer
who was unaware of patient identity and the first observer’s
results analyzed the same patients’ data in the same way.
Statistical analysis. All values are expressed as a mean 
SD. The Student t test was used to compare the difference
between the two groups. Linear regression was used to
investigate the correlation between two parametric variables.
Data were analyzed using standard statistical software
(SPSS, version 11.0, Chicago, Illinois). A p value 0.05
was considered statistically significant.
RESULTS
Clinical characteristics. Table 1 summarizes the clinical
characteristics of the two groups, who had comparable mean
age, HR, cardiac medications, resting diastolic BP and peak
BPs, smoking history, and LV systolic and diastolic func-
tion. Diabetic patients showed a greater prevalence of
obesity than controls.
Echocardiographic characteristics. Table 2 shows the
clinical characteristics of diabetic patients, and Table 3
summarizes the echocardiographic features of the diabetic
and control groups. In the diabetic group, basal segment
resting Sm and Em were significantly lower than those in
controls. Diabetic duration and indexes of diabetic control
(glycosylated hemoglobin or blood glucose) were not corre-
lated with resting Sm or Em. There were no significant
differences in resting Sm and Em in subgroups of patients
with or without complications (e.g., nephropathy, retinop-
athy, and neuropathy). These parameters did not differ




(n  41) p Value
Age (yrs) 56  8 59  9 NS
Resting HR (beats/min) 72  13 75  11 NS
Peak HR (beats/min) 143  8 140  11 NS
Resting SBP (mm Hg) 133  23 141  28 NS
Resting DBP (mm Hg) 74  12 76  14 NS
Peak SBP (mm Hg) 170  30 158  38 NS
Peak DBP (mm Hg) 81  14 74  15 0.034
Weight (kg) 76  16 89  21 0.007
Body mass index (kg/m2) 27  5 30  7 0.01
Hypertension 20/41 (49) 24/41 (59) NS
Hypercholesterolemia 12/35 (34) 24/40 (60) 0.026
Smoker 8/34 (24) 10/40 (25) NS
Beta-blockers 9/41 (22) 12/41 (29) NS
Nitrates 7/41 (17) 9/41 (22) NS
Calcium blockers 3/41 (7) 8/41 (20) NS
ACE inhibitors 11/41 (27) 16/41 (39) NS
Data are presented as the mean value  SD or n/N (%) of patients.
ACE  angiotensin-converting enzyme; DBP  diastolic blood pressure; DM 
diabetes mellitus; HR  heart rate; NS  nonsignificant; SBP  systolic blood
pressure.
Table 2. Clinical Characteristics of Diabetic Patients (n  41)
History of diabetes
Duration (yrs) 11  10
Type I 5 (12)
Complications of diabetes
Stroke 2 (5)
Peripheral vascular disease 9 (22)




HbA1C (%) 7.4  2.0
Glucose (mmol/l) 10.5  4.8
Creatinine (mol/l) 0.10  0.1
Urea (mmol/l) 8.1  4.1
Lipid profile
Total cholesterol (mmol/l) 4.9  1.0
LDL cholesterol (mmol/l) 2.4  0.9
HDL cholesterol (mmol/l) 1.3  0.5
TG (mmol/l) 2.1  1.1
Diabetic treatment
Insulin 10 (24)
Diet therapy 5 (12)
Metformin 11 (27)
Sulfonylureas 18 (44)
Data are presented as the mean value  SD or number (%) of patients.
HbA1C  glycosylated hemoglobin; HDL  high-density lipoprotein; LDL 
low-density lipoprotein; TG  triglycerides.




(n  41) p Value
LVEDD (cm) 4.6  0.4 4.6  0.5 NS
IVSD (cm) 1.0  0.2 1.1  0.1 0.008
PWD (cm) 1.0  0.2 1.0  0.1 NS
LVFS (%) 29  4 29  4 NS
LVMI (g/m2) 92  21 96  21 NS
LVEDV (ml) 86  32 93  23 NS
LVESV (ml) 32  14 37  16 NS
LVEF (%) 63  7 62  5 NS
E (m/s) 0.82  0.23 0.81  0.18 NS
A (m/s) 0.75  0.31 0.82  0.25 NS
E/A ratio 1.20  0.51 1.04  0.33 NS
DT (ms) 233  80 248  52 NS
Resting Sm (cm/s) 4.7  0.9 4.2  0.9 0.012
Resting Em (cm/s) 5.8  1.5 4.2  1.2 0.001
Data are presented as the mean value  SD.
A  mitral late peak velocity; DM  diabetes mellitus; DT  mitral valve
deceleration time; E  mitral early peak velocity; E/A  ratio of early to late peak
diastolic transmitral flow velocity; Em  peak myocardial early velocity; IVSD 
inter-ventricular septal dimension; LV  left ventricular; LVEDD  left ventricular
end-diastolic dimension; LVEDV  left ventricular end-diastolic volume; LVEF 
left ventricular ejection fraction; LVESV  left ventricular end-systolic volume;
LVFS  left ventricular fractional shortening; NS  nonsignificant, PWD 
end-diastolic posterior wall thickness; Sm  peak myocardial systolic velocity.
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according to treatment with and without angiotensin-
converting enzyme inhibitors or between patients treated
with insulin or oral hypoglycemic drugs.
Sm and Em. Figure 2 shows Sm and Em in diabetic and
control groups in relation to different stages of DbE. Both
Sm and Em were significantly correlated from the rest to
Figure 2. The tissue Doppler imaging-derived myocardial peak systolic velocity (Sm) (A) and myocardial peak early diastolic velocity (Em) (B) values from
rest to peak dobutamine stress in diabetic patients (DM) and control subjects.
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peak stage. In the diabetic group, Sm was significantly lower
than in the control subjects at baseline (4.2  0.9 cm/s vs.
4.7 0.9 cm/s, p 0.012). In a linear model, diabetes (p
0.012) and ejection fraction (p  0.042) were independent
predictors of resting Sm. As previously described, Sm
showed a progressive increase from resting to peak DbE in
both groups. However, Sm at a low dose (6.0  1.3),
pre-peak (8.4  1.8), and peak stress (8.9  1.8) in diabetic
patients was not significantly different from that in controls
(6.3  1.4, 8.9  1.6, and 9.6  2.1 cm/s, respectively).
The absolute increase (4.7  1.6 vs. 4.9  1.9 cm/s) and
relative increase (115  42% vs. 108  49%) in Sm from
resting to peak stage were similar in the diabetic versus the
control group, respectively.
Resting Em in the diabetic group was significantly lower
than that in the control group (4.2 1.2 vs. 5.8 1.5 cm/s,
p  0.001). In a linear model, diabetes (p  0.001),
hypertension (p  0.039), HR (p  0.009), age (p 
0.001), mitral inflow E velocity (p  0.001), and E/A (p 
0.001) were associated with resting Em, but only diabetes (p
 0.001), E (p  0.002) and E/A (p  0.001) were
independent predictors of resting Em.
The Em also showed a progressive increase from resting
to peak DbE in both groups. In the diabetic group, the
Em ([cm/s] low dose: 5.0  1.4; pre-peak: 5.3  1.1; peak:
5.9  1.5) was significantly lower than that in the control
group (low dose: 6.6  1.5; pre-peak: 6.9  1.3; peak:
7.3  1.7; all p  0.001). However, the absolute increase
(1.7  1.5 vs. 1.6  1.2 cm/s) and relative increase (49 
58% vs. 30  26%) in Em from resting to peak dose
were also similar in the diabetic versus control groups,
respectively.
Inter-observer and intra-observer variabilities. There
were no significant differences in Sm and Em between the
first measurement (7.2  2.7 and 6.3  1.9 cm/s, respec-
tively) and the second measurement of the same observer
(7.4  3.0 cm/s, r  0.98, p  0.001 and 6.4  2.0 cm/s,
r  0.96, p  0.001, respectively) or a second observer (6.7
 2.8 cm/s, r  0.96, p  0.001 and 6.1  1.9 cm/s, r 
0.93, p  0.001, respectively). Mean absolute differences in
Sm and Em were 0.4  0.5 cm/s (range 0.0 to 2.3) and 0.4
 0.4 cm/s (range 0.0 to 1.6) between the two measure-
ments by the same observer and 0.7  0.6 cm/s (range 0.0
to 2.2) and 0.5  0.5 cm/s (range 0.0 to 2.0) between the
two observers.
DISCUSSION
Experimental and clinical evidence has shown that diabetes
is associated with LV systolic and diastolic dysfunction.
This study shows that sensitive indexes of systolic and
diastolic function are abnormal in diabetic patients with a
normal ejection fraction and without coronary heart disease
and LV hypertrophy. However, the absence of an abnormal
response to stress argues against a role for ischemia in the
etiology of this dysfunction.
Application of TDI techniques to myocardial assess-
ment. In diabetic patients without overt evidence of heart
disease, in whom the ejection fraction is normal at rest, a
number of studies have demonstrated abnormal patterns
of diastolic inflow, suggesting underlying disturbances of
compliance or relaxation (19). Unfortunately, transmitral
flow is determined by filling pressure as well as LV relax-
ation and compliance. Tissue Doppler-derived parameters
have the benefit of being less load-dependent and of
being sensitive to changes not identified by conventional
mitral Doppler inflow indexes (20,21). Moreover, Shan et
al. (22) have shown Em to be inversely related to interstitial
fibrosis.
Although the ejection fraction is used to assess global
LV function, it is very load-dependent, may be influenced
by compensatory hyperkinesia, and is an insensitive measure
of systolic function. In contrast, measurement of the ven-
tricular long-axis velocities using TDI is thought to pro-
vide a more sensitive index of systolic function than LV
ejection fraction, as it reflects the subendocardial position
of the longitudinal fibers, which are vulnerable to ischemia,
LV hypertrophy, and other abnormalities of activation and
relaxation (23). The results of this study add diabetes to a
number of disorders where TDI has identified subtle ab-
normalities of systolic base-apex function in patients
with normal or mildly impaired LV systolic function (5–
7,20).
Causes of subclinical LV dysfunction in diabetes.
Regional function is dependent on the number of normally
functioning myocytes and the status of the cardiac intersti-
tium. In diabetic subjects, myocytes may be abnormal
because of hypertrophy, ischemia, or metabolic distur-
bances. We believe that hypertrophy is an unlikely explana-
tion, as the selection of patients avoided those with in-
creased LV mass. A reduction of coronary perfusion is
possible due to epicardial disease or small-vessel disease, but
the presence of normal coronary angiograms, normal do-
butamine echocardiograms, and the preservation of systolic
reserve (an increment of velocity with dobutamine) all argue
against an ischemic etiology for this resting dysfunction. This is
also supported by previous studies showing no difference in
small-vessel pathology and luminal area between diabetic
and nondiabetic subjects without significant CAD and with
normal LV mass (24) as well as the presence of modestly
increased LV end-diastolic pressure, decreased LV compli-
ance, and even a low ejection fraction with diffuse hypoki-
nesia in diabetic patients after exclusions of CAD by
coronary angiography and small-vessel disease by atrial
pacing (3). A metabolic disturbance associated with reduced
force generation cannot be excluded by this study, but it
seems less likely in the absence of an apparent relationship
with diabetic control.
As changes were detected in the absence of hypertrophy
and ischemia and were not altered by stress, the findings of
this study would be consistent with myocardial fibrosis
being the main cause of the myocardial functional changes
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(25). This is because the interstitium has a more important
role—relative to myocyte function—at rest than it does at
stress, when contractile behavior increases several-fold but
the elastic component remains the same. An alternate
explanation is that the contractile response is preserved
because diabetic neuropathy and adrenoreceptor supersen-
sitivity may play a role in provoking a blunted inotropic
response to dobutamine. Indeed, this interpretation is con-
sistent with the hypothesis that diabetic heart disease is
related to defects in calcium transportation, myocardial
contractile protein collagen formation, and fatty acid me-
tabolism, leading to myocyte hypertrophy and myocardial
fibrosis. Interstitial collagen accumulation has been shown
to be associated with enhanced diastolic stiffness in a dog
model of diabetes (26), and likewise, the extent and pro-
gressive increase in these abnormalities have been thought
to contribute to measurable diastolic dysfunction of diabetic
patients (27). The resulting disturbances in diastolic func-
tion may explain the clinical presentation of heart failure
symptoms in diabetic patients.
Study limitations. Exclusion of an ischemic contribution
was based on a normal dobutamine echocardiogram, to-
gether with a normal coronary angiogram, in 13 patients.
The possibility of false-negative studies cannot be excluded,
as more uniform application of invasive techniques (e.g.,
coronary angiography and flow reserve) would not be
ethically applicable in these asymptomatic patients, and
positron emission tomography was not available. However,
the lack of coronary disease was supported by the lack of a
decrement of velocity with dobutamine in the diabetic
group.
The control group was comprised of a nondiabetic
population considered to have a low probability of coronary
disease on clinical grounds and having a normal dobutamine
echocardiogram. It is possible that their clinical status may
have affected the control group results, but we consider this
unlikely because this group was well matched with the
diabetic subjects (Tables 1 and 3).
Doppler techniques are also angle-dependent and may be
influenced by the translational movement of the heart
during dobutamine stress. However, we excluded segments
with an angle 20° between the Doppler beam and the
longitudinal walls, or a change of image orientation 20°
among the stages of dobutamine stress, which should
minimize this source of error.
Conclusions. This study demonstrates that abnormalities
of systolic and diastolic function are prevalent in diabetic
patients, despite the absence of overt systolic dysfunction
or CAD and LV hypertrophy. Diabetic patients do not
show an abnormal response to stress, suggesting that
small-vessel disease may not play a causative role in early
diabetic cardiomyopathy. Quantitative assessment of Sm
and Em using TDI techniques offers a feasible approach to
the assessment of subclinical LV function and may allow
the early detection of diabetic heart disease.
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